The German Federal Joint Committee (G-BA) today has confirmed that the largest defined patient group has "considerable" (beträchtlichen) additional benefit of Halaven (eribulin) versus certain comparator therapies as determined by the G-BA. Eribulin is approved for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.

"The G-BA has made an encouraging decision potentially relevant for thousands of women in Germany with advanced breast cancer. Last year's indication extension for eribulin also means that women can have access to this important and effective treatment option earlier on. Eribulin remains the only single-agent chemotherapy proven to extend overall survival in metastatic breast cancer after anthracycline and taxane treatment, and this positive decision by the G-BA will be welcomed by physicians and patients across the country," said Dr Christian Jackisch, Professor of Obstetrics and Gynaecology at the Breast Cancer Center Klinikum Offenbach, Germany.

For more details, go to: http://www.firstwordpharma.com/node/1259368#axzz3PxgDukaO